Shannon Klinger - Novartis Executive
| NVSN Stock | MXN 2,004 134.33 6.28% |
Executive
Ms. Shannon Thyme Klinger was Group General Counsel, Member of the Executive Committee of Novartis Inc. since June 1, 2018. She was Chief Ethics, Risk and Compliance Officer, Member of the Executive Committee at the Company from April 1, 2018. Before that, she was Chief Ethics and Compliance Officer and Global Head of Litigation. She joined Novartis in 2011 as General Counsel, North America, for Sandoz in the United States and later became the Global Head of Legal and General Counsel for Sandoz International GmbH. Prior to Novartis, Ms. Klinger worked in the United States as a partner at Mayer Brown LLP from 2010 to 2011, senior vice president and general counsel for Solvay Pharmaceuticals Inc. from 2008 to 2010, and vice president of marketing compliance and associate counsel for Barr LaboratoriesDuramed Pharmaceuticals from 2005 to 2007. She was also a partner at Alston Bird LLP, where she focused on litigation and antitrust, pharmaceutical legal and regulatory matters since 2018.
| Age | 48 |
| Tenure | 6 years |
| Phone | 41 61 324 1111 |
| Web | https://www.novartis.com |
Novartis Management Efficiency
The company has return on total asset (ROA) of 0.0645 % which means that it generated a profit of $0.0645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1093 %, meaning that it generated $0.1093 on every $100 dollars invested by stockholders. Novartis' management efficiency ratios could be used to measure how well Novartis manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 3 records | EXECUTIVE Age | ||
| Jeffrey Pott | AstraZeneca PLC | N/A | |
| David Redfern | GlaxoSmithKline plc | 57 | |
| Adrian Kemp | AstraZeneca PLC | N/A | |
Management Performance
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0645 |
Novartis AG Leadership Team
Elected by the shareholders, the Novartis' board of directors comprises two types of representatives: Novartis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novartis. The board's role is to monitor Novartis' management team and ensure that shareholders' interests are well served. Novartis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novartis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steffen Lang, Global Head of Novartis Technical Operations, Member of the Executive Committee | ||
| Paul Penepent, Head Accounting | ||
| Joerg Reinhardt, Independent Non-Executive Chairman of the Board | ||
| Ton Buechner, Non-Executive Independent Director | ||
| Robert PharmD, Chief Officer | ||
| Karen Hale, Chief Officer | ||
| Charles Sawyers, Non-Executive Independent Member of the Board | ||
| Steven Baert, Chief People & Organization Officer, Member of the Executive Committee | ||
| John Tsai, Head of Global Drug Development and Chief Medical Officer, Member of the Executive Committee | ||
| Richard Saynor, Chief Executive Officer of Sandoz, Member of the Executive Committee | ||
| Frans Houten, Non-Executive Independent Director | ||
| Nancy Andrews, Non-Executive Independent Director | ||
| Daniel Vasella, Honorary Chairman of the Board | ||
| Susanne Schaffert, President of Novartis Oncology, Member of the Executive Committee | ||
| Enrico Vanni, Lead Independent Non-Executive Vice Chairman of the Board | ||
| Bertrand Bodson, Chief Digital Officer, Member of the Executive Committee | ||
| Robert Weltevreden, Head of Novartis Business Services (NBS), Member of the Executive Committee | ||
| Elizabeth Doherty, Non-Executive Independent Director | ||
| Vasant Narasimhan, Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee | ||
| Alex Krauer, Honorary Chairman of the Board | ||
| Patrice Bula, Non-Executive Independent Director | ||
| Charlotte PamerWieser, Corporate Secretary | ||
| Shannon Klinger, Chief Risk and Compliance Officer, Group General Counsel | ||
| Andreas Planta, Non-Executive Independent Director | ||
| William Winters, Non-Executive Independent Member of the Board | ||
| Ann Fudge, Non-Executive Independent Director | ||
| Srikant Datar, Non-Executive Independent Director | ||
| MarieFrance Tschudin, President of Novartis Pharmaceuticals, Member of the Executive Committee | ||
| Samir MD, Global Relations | ||
| Simon Moroney, Non-Executive Independent Director | ||
| James Bradner, President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee | ||
| Klaus Moosmayer, Chief Ethics, Risk and Compliance Officer, Member of the Executive Committee | ||
| Harry Kirsch, Chief Financial Officer, Member of the Executive Committee | ||
| Bridgette Heller, Non-Executive Independent Director |
Novartis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novartis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0645 | |||
| Profit Margin | 0.13 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 4.12 T | |||
| Shares Outstanding | 2.12 B | |||
| Shares Owned By Institutions | 8.23 % | |||
| Price To Earning | 24.95 X | |||
| Price To Book | 2.82 X | |||
| Price To Sales | 74.58 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Novartis Stock Analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.